Page 17 - Celularity Inc News Today

Press release content from Business Wire. The AP news staff was not involved in its creation. Global Mesenchymal Stem Cells Advances and Applications Market Report 2021 - ResearchAndMarkets.com February 12, 2021 GMT DUBLIN--(BUSINESS WIRE)--Feb 12, 2021-- As the most common stem cell type being used within regenerative medicine today, there is huge potential for growth within the MSC market. There are more than one-hundred thousand scientific publications published about MSCs, as well as over 1...

Big Rock Partners Acquisition Corp. (NASDAQ: BRPA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the proposed merger of BRPA and NeuroRx, Inc. If you are an investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780. Collective Growth Corporation (NASDAQ: CGRO)  Lifshitz Law Firm, P.C. announces investigation in...

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of ANCN, JWS, GXGX, ... Rigrodsky Law, P.AJanuary 26, 2021 GMT WILMINGTON, Del., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating: Anchiano Therapeutics Ltd. (NASDAQ GS: ANCN ) regarding possible breaches of fiduciary duties and other violations of law related to Anchiano Therapeutics’ ...

Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating GX Acquisition Corp. ("GXGX" or the "Company") ( ) relating to its proposed merger with Celularity, Inc. Under the terms of the agreement, GXGX will acquire Celularity through a reverse merger, with Celularity emerging as a publicly traded company. The investigation focuses on whether GX Acquisition Corp. and its Board of Directors viola...

Posted on 7440 Wren Therapeutics Ltd., (“Wren”), a biopharmaceutical company pioneering a unique network kinetics approach to drug discovery for protein misfolding diseases, today announced the closing of a £12.4 million (c. $17.0 million) financing. This financing brings the total capital raised to date to approximately £33 million (c. $45 million). The financing was led by existing shareholder The Baupost Group, with particip...

Press release content from Business Wire. The AP news staff was not involved in its creation. Wren Therapeutics Announces Financing of £12.4 Million (c. $17.0 Million) January 25, 2021 GMT CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Jan 25, 2021-- Wren Therapeutics Ltd., (“Wren”), a biopharmaceutical company pioneering a unique network kinetics approach to drug discovery for protein misfolding diseases, today announced the closing of a £12.4 million (c. $17.0 million) financing. This fina...

WILMINGTON, Del., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating GX Acquisition Corp. ("GX Acquisition") (NADAQ ...

Share this article Share this article FLORHAM PARK, N.J., Jan. 20, 2021 /PRNewswire/ -- Celularity Inc., a clinical stage cell therapeutics company focused on the development of innovative allogeneic placenta-derived cellular therapies, today announced that Robert J. Hariri, M.D., Ph.D., Founder, Chairperson and Chief Executive Officer of Celularity and members of the management team will be participating in a fireside chat at the B. Riley Virtual Oncology Investor Conference on Thursday, Janu...